Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

E. Van Cutsem · SciRah

Researcher profile · Semantic Scholar

E. Van Cutsem

Share profile

E. Van Cutsem — researcher profile on SciRah

h-index: 179
Works: 1,874
Citations: 169K

Most-cited papers

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.
Y. Janjigian, S. Al-Batran, Z. Wainberg, K. Muro +23 more
2025New England Journal of Medicine259 citations
Semantic Scholar
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.
Thierry Andre, E. Élez, H. Lenz, Lars Henrik Jensen +25 more
2025The Lancet154 citations
Semantic Scholar
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
S. Kopetz, T. Yoshino, E. Van Cutsem, C. Eng +11 more
2025Nature Medicine115 citations Open access
Semantic Scholar
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer.
K. Shitara, E. Van Cutsem, M. Gümüş, S. Lonardi +21 more
2025New England Journal of Medicine104 citations
Semantic Scholar
Encorafenib, Cetuximab and mFOLFOX6 in BRAF-mutant Colorectal Cancer
E. Élez, T. Yoshino, Lin Shen, S. Lonardi +16 more
2025New England Journal of Medicine103 citations Open access
Semantic Scholar
Tumor Treating Fields with gemcitabine and nab-paclitaxel for locally advanced pancreatic adenocarcinoma: randomized, open-label, pivotal phase 3 PANOVA-3 study
Hani M. Babiker, V. Picozzi, S. Chandana, B. Melichar +18 more
2025Journal of Clinical Oncology38 citations Open access
Semantic Scholar
Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): First results of overall survival (OS) from CheckMate 577.
R. Kelly, J. Ajani, J. Kużdżał, Thomas Zander +16 more
2025Journal of Clinical Oncology36 citations
Semantic Scholar
NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial
Zhi-Hao Lu, Wenting Du, Xi Jiao, Yan-Ni Wang +14 more
2025Journal of Clinical Oncology18 citations Open access
Semantic Scholar
Final analysis of the randomized phase 2 part of the ASPEN-06 study: A phase 2/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric/gastroesophageal cancer (GC).
K. Shitara, Z. Wainberg, J. Tabernero, E. Van Cutsem +13 more
2025Journal of Clinical Oncology17 citations
Semantic Scholar
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis
J. Strickler, A. Cercek, S. Siena, T. André +19 more
2026Nature Communications13 citations Open access
Semantic Scholar
Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC).
Y. Janjigian, S. Al-Batran, Z. Wainberg, K. Muro +16 more
2025Journal of Clinical Oncology12 citations Open access
Semantic Scholar
Preliminary results from a randomized, open-label, phase 2 study of botensilimab (BOT) with or without balstilimab (BAL) in refractory microsatellite stable metastatic colorectal cancer with no liver metastases (MSS mCRC NLM).
M. Fakih, N. Segal, Benjamin L. Schlechter, Thierry Andre +16 more
2025Journal of Clinical Oncology11 citations
Semantic Scholar
The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer.
C. Leonhardt, M. Adham, S. Bazarbashi, I. Ben-Aharon +63 more
2026The Lancet Oncology9 citations
Semantic Scholar
Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database
J. Bachet, A. de Gramont, M. Raeisi, Manel Rakez +17 more
2025Journal of Clinical Oncology9 citations Open access
Semantic Scholar
Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial
D. Melisi, T. Macarulla, C. de la Fouchardière, R. Pazo Cid +14 more
2025ESMO Open7 citations Open access
Semantic Scholar
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2
S. Stintzing, J. Tabernero, T. Satoh, A. Dasari +17 more
2025ESMO Open7 citations Open access
Semantic Scholar
Zolbetuximab + pembrolizumab and chemotherapy as first-line treatment for patients with CLDN18.2-positive, HER2-negative, PD-L1-positive locally advanced unresectable or metastatic G/GEJ adenocarcinoma: Phase 3, double-blind, randomized trial (LUCERNA).
K. Shitara, P. Enzinger, F. Lordick, Elizabeth Smyth +6 more
2026Journal of Clinical Oncology6 citations
Semantic Scholar
Inflammation and mutational burden differentially associated with nivolumab or ipilimumab combination efficacy in colorectal cancer
Ming Lei, M. Overman, Jin Yao, T. André +20 more
2025Nature Communications6 citations Open access
Semantic Scholar
Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study
Paul E. Oberstein, J. R. Hecht, K. Raghav, Filippo Pietrantonio +42 more
2026Journal of Clinical Oncology5 citations Open access
Semantic Scholar
BREAKWATER: Primary analysis of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).
S. Kopetz, H. Wasan, T. Yoshino, T. W. Kim +11 more
2026Journal of Clinical Oncology5 citations
Semantic Scholar
BREAKWATER: Analysis of first-line encorafenib + cetuximab + chemotherapy in BRAF V600E-mutant metastatic colorectal cancer.
S. Kopetz, T. Yoshino, E. Van Cutsem, C. Eng +11 more
2025Journal of Clinical Oncology5 citations Open access
Semantic Scholar
Long-term recurrence patterns in rectal cancer after neoadjuvant therapy: 25-years of real-world data.
Pieter Maerten, G. Defraene, A. Wolthuis, C. Schraepen +15 more
2025European Journal of Cancer5 citations
Semantic Scholar
Comparison of inter- and intraobserver agreement between [18F]AlF-NOTA-octreotide and [68Ga]Ga-DOTA-SSA PET/CT
H. Leupe, Niloefar Ahmadi Bidakhvidi, K. Goffin, Bliede Van den Broeck +13 more
2025EJNMMI Reports5 citations Open access
Semantic Scholar
NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial
T. Macarulla, R. Cid, M. Womack, A. C. Gracián +16 more
2026ESMO Open4 citations Open access
Semantic Scholar
729MO Circulating tumour (ct) DNA analysis of BRAF V600E dynamics and changes in genomic landscape in patients (pts) with first-line (1L) BRAF V600E-mutant metastatic colorectal cancer (mCRC) treated in BREAKWATER
S. Kopetz, K. Shah, T. Yoshino, R. Yaeger +12 more
2025Annals of Oncology4 citations Open access
Semantic Scholar
LBA4 Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma
S. Al-Batran, Z. Wainberg, K. Muro, D. Molena +16 more
2025Annals of Oncology4 citations
Semantic Scholar
TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma.
P. Hammel, J. Metges, Teresa Macarulla Mercade, R. García-Carbonero +31 more
2025Journal of Clinical Oncology4 citations
Semantic Scholar
Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC (European Network for GI Cancers) initiative
J. Taieb, J. Seligmann, D. Modest, C. Girault +153 more
2025ESMO Open4 citations Open access
Semantic Scholar
Association between neutropenia and efficacy in patients with refractory mCRC receiving trifluridine/tipiracil + bevacizumab: post hoc analysis of the SUNLIGHT trial
G. Prager, E. Elez, M. Fakih, F. Ciardiello +5 more
2025ESMO Gastrointestinal Oncology4 citations Open access
Semantic Scholar
Impact of RAS/BRAF V600E mutations on the tumor immune microenvironment in mismatch repair deficient /microsatellite instability colorectal cancers.
Mohamed E. Salem, A. Puccini, E. Mauer, T. André +9 more
2025Clinical Cancer Research4 citations
Semantic Scholar
BREAKWATER: Progression-free and overall survival analyses of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).
S. Kopetz, J. Tabernero, S. Lonardi, Lin Shen +16 more
2026Journal of Clinical Oncology3 citations
Semantic Scholar
BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings
James J. Harding, R. Hofheinz, E. Élez, Y. Kuboki +14 more
2026Cancer Research Communications3 citations Open access
Semantic Scholar
A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3.
S. Kopetz, J. Tabernero, S. Lonardi, L. Shen +16 more
2026Annals of Oncology3 citations Open access
Semantic Scholar
LBA29 Nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): New results from CheckMate 8HW
S. Lonardi, H. Lenz, E. E. Fernandez, L. Jensen +16 more
2025Annals of Oncology3 citations
Semantic Scholar
Amivantamab with or without chemotherapy in right-sided metastatic colorectal cancer: Updated results from OrigAMI-1, an open-label, phase 1b/2 study.
K. Raghav, E. Van Cutsem, Dirk Arnold, Paul E. Oberstein +15 more
2025Journal of Clinical Oncology3 citations
Semantic Scholar
First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): Progression-free survival and updated overall survival analyses.
E. Élez, T. Yoshino, Lin Shen, S. Lonardi +16 more
2025Journal of Clinical Oncology3 citations
Semantic Scholar
Surgical journey for participants (pts) in the MATTERHORN trial: A global, randomized, phase 3 study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma.
D. Molena, J. Woo, Z. Wainberg, M. Liberman +16 more
2026Journal of Clinical Oncology2 citations
Semantic Scholar
Exploratory analysis of HER2 status based on central and local testing results from the DESTINY-Gastric04 study.
K. Shitara, E. Van Cutsem, Lin Shen, F. Pietrantonio +12 more
2026Journal of Clinical Oncology2 citations
Semantic Scholar
Management of colorectal cancer in older adults: an expert panel recommendation to guide daily clinical practice.
G. Liposits, Thierry Andre, T. Aparicio, I. Montroni +12 more
2026The Lancet Gastroenterology and Hepatology2 citations
Semantic Scholar
Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer: An analysis of 18,041 patients in the ARCAD CRC database.
A. D. Wagner, M. Raeisi, Manel Rakez, R. Diasio +12 more
2026European Journal of Cancer2 citations
Semantic Scholar
Multi-omic biomarkers of neoadjuvant treatment response in rectal cancer: A narrative review.
Pieter Maerten, A. Wolthuis, A. D'Hoore, G. Bislenghi +10 more
2026European Journal of Surgical Oncology2 citations
Semantic Scholar
Response to Letter to the Editor: ‘NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial’
T. Macarulla, R. Cid, M. Womack, A. C. Gracián +16 more
2026ESMO Open2 citations Open access
Semantic Scholar
Associations between early tumor shrinkage/depth of response and survival from the ARCAD database
H. Bando, Y. Takeda, Toshihiro Misumi, Tomomi Nishikawa +15 more
2025JNCI Cancer Spectrum2 citations Open access
Semantic Scholar
Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer
J. Taieb, M. Fakih, G. Liposits, G. Prager +8 more
2025Frontiers in Oncology2 citations Open access
Semantic Scholar
270O Efficacy and safety of perioperative durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma in Asia: A subgroup analysis of the MATTERHORN trial
Y. Janjigian, K. Muro, S. Al-Batran, Z. Wainberg +16 more
2025Annals of Oncology2 citations
Semantic Scholar
Progression-free survival for unresectable non-metastatic locally advanced pancreatic cancer after surgical microwave ablation plus durvalumab and tremelimumab: phase-2 non-randomized prospective clinical trial
H. Topal, T. Venken, A. Bassez, G. Chiritescu +4 more
2025Communications Medicine2 citations Open access
Semantic Scholar
Managing adverse events in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in combination with bevacizumab
M. Fakih, F. Ciardiello, G. Prager, E. Élez +4 more
2025ESMO gastrointestinal oncology2 citations Open access
Semantic Scholar
Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial.
J. Taieb, D. Modest, M. Fakih, F. Ciardiello +8 more
2025European Journal of Cancer2 citations Open access
Semantic Scholar
389MO Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in patients (pts) with locally advanced (LA) esophageal squamous cell carcinoma (ESCC): RATIONALE-306 subgroup analysis
E. Van Cutsem, J. Xu, E. Raymond, R. Hubner +15 more
2025Annals of Oncology2 citations
Semantic Scholar
The ongoing first-line treatment race for metastatic pancreatic ductal adenocarcinomas: will a tough disease lose its horror?
W. Dempke, C. Sippel, K. Fenchel, V. Heinemann +2 more
2026Future Oncology1 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Tabernero×14
Invite
J. Tabernero — researcher profile on SciRah
E. Élez×11
Invite
E. Élez — researcher profile on SciRah
Z. Wainberg×10
Invite
Z. Wainberg — researcher profile on SciRah
C. Eng×10
Invite
C. Eng — researcher profile on SciRah

×9

Invite

S. Kopetz — researcher profile on SciRah

Invite

H. Wasan — researcher profile on SciRah

F. Ciardiello×8

Invite

F. Ciardiello — researcher profile on SciRah

Invite

R. Yaeger — researcher profile on SciRah

Invite

S. Lonardi — researcher profile on SciRah

Xiao-Song Zhang×7

Invite

Xiao-Song Zhang — researcher profile on SciRah

Invite

T. Maughan — researcher profile on SciRah

Y. Janjigian×6

Invite

Y. Janjigian — researcher profile on SciRah